BioSpace News Archive

San Francisco-based Mammoth Biosciences, co-founded by one of the originators of CRISPR gene editing, Jennifer Doudna, closed on a $23 million Series A financing round.

The Cancer Prevention Institute of California (CPIC), located in Fremont, California, announced it was disbanding after 44 years. The reason for the closing, it indicates, is lack of federal funding.

Shionogi, based in Osaka, Japan and Florham Park, New Jersey, announced that the U.S. Food and Drug Administration (FDA) approved Mulpleta (lusutrombopag) for thrombocytopenia in adults with chronic liver disease who were about to have a medical procedure performed.

Laekna, headquartered in Shanghai, China, signed a deal with Novartis Pharma AG for exclusive worldwide rights to two oral Novartis clinical-stage cancer drugs.

NewLink Genetics has announced, with the company restructuring and layoffs, they are refocusing on indoximod.

London-based ReViral announced the completion of a Series B financing worth $55 million. The financing was jointly led by New Leaf Venture Partners and Novo Ventures, part of Novo Holdings, with new investors Perceptive Advisors. Existing investors also participated, including Andera Partners, OrbiMed and Brace Pharma Capital.

ARCA Biopharma, located in Westminster, Colorado, announced mixed but positive outcomes from a Phase II clinical trial of its beta-blocker Gencaro for atrial fibrillation (AF) patients with heart failure (HF).

Chinese biotech company Ascletis Pharma debuted on the Hong Kong stock exchange, rising as much as 6.4 percent, but ending the day where it started.

Fearing disruption of drug inventories when Brexit takes place, Sanofi, AstraZeneca and Novartis have indicated they are stockpiling drugs.

In response to the opioid crisis, particularly as the federal government cracks down on opioid use, physicians are increasingly using non-opioid therapeutics off-label in response. This has at least some physicians and one pharma company concerned.